Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19

Yan Tang, David J. Kwiatkowski, Elizabeth P. Henske
European Respiratory Journal 2021 57: 2002737; DOI: 10.1183/13993003.02737-2020
Yan Tang
1Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Kwiatkowski
1Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
2D.J. Kwiatkowski and E.P. Henske contributed equally to this article as lead authors and supervised the work
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth P. Henske
1Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
2D.J. Kwiatkowski and E.P. Henske contributed equally to this article as lead authors and supervised the work
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Increased pneumocyte expression of the SARS-CoV-2 entry receptor ACE2 in lymphangioleiomyomatosis (LAM) is associated with upregulation of interferon pathways in natural killer cells as well as increased IL6 expression in LAM-associated fibroblasts https://bit.ly/34ChSsg

To the Editor:

Respiratory failure is among the gravest outcomes of coronavirus disease 2019 (COVID-19), and most of the severe cases are associated with significant lung comorbidities [1]. Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease of women caused by mutations in tuberous sclerosis genes, resulting in aberrant hyperactivation of the mTOR complex 1 (mTORC1) signalling network in LAM cells, which are of mesenchymal origin [2]. The risk of COVID-19 in LAM is unknown.

We profiled the explant lungs of five women with LAM (46 659 cells) by single cell RNA sequencing (scRNA-seq) using 10× genomics Chromium platform. Low quality cells, defined as cells in which fewer than 200 different genes were detected or with mitochondrial gene percentage higher than 10%, were filtered out. Raw data was normalised, and log transformed as previously described [3]. Batch effects of datasets from different platforms were removed, and datasets were integrated using Seurat [4]. Major cell types identified in LAM using the algorithm SingleR [5] (figure 1a) included epithelial cells (type I and type II pneumocytes, ciliated cells), immune cells (T cells, B cells, macrophages, dendritic cells, natural killer cells) and endothelial cells (lymphatic endothelial cells and blood endothelial cells). The cell type annotation was further confirmed by plotting marker genes manually. Re-clustering of pneumocytes showed that ACE2 was primarily expressed in type II pneumocytes, while TMPRSS2 was expressed in all epithelial cell types (figure 1a), consistent with prior data [6–8]. The LAM lungs were compared with existing scRNA-seq datasets (GSE122960) of healthy lungs (n=8) [9], derived from donors who had died from stroke, haemorrhage, brain injury or gunshot. One healthy control with an Asian genetic background was excluded because of reports that Asian individuals have higher expression of ACE2 than other populations [10].

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Expression of ACE2 and TMPRSS2 by epithelial cells is upregulated in lymphangioleiomyomatosis (LAM) lungs, which is linked with upregulation of interferon (IFN) pathways and IFN-γ expression in natural killer (NK) cells as well as increased interleukin (IL)-6 expression in LAM-associated fibroblasts. a) Increased expression of ACE2 and TMPRSS2 in LAM. UMAP plot shows major cell types identified in five LAM lung specimens. Re-clustering of pneumocytes showed that ACE2 was expressed primarily in type II pneumocytes, while TMPRSS2 was expressed by all subtypes. Scale bar colour intensity represents normalised expression. Significantly higher percentage of type II pneumocytes expressed ACE2 and TMPRSS2 in LAM lungs compared to healthy human lungs (Mann–Whitney U-test). Violin plot showing highest coronavirus disease 2019 (COVID-19) score in ACE2+/TMPRSS2+ cells. b) Interferon secretion by LAM NK cells may cooperate with IL-6 to upregulate ACE2 expression in LAM epithelial cells. In the IL-6-induced acute phase response pathway, master transcription factor STAT3 and four downstream genes were significantly upregulated in ACE2+ epithelial cells. LAM-associated fibroblasts showed upregulation of IL6 expression compared to fibroblasts derived from healthy lungs. Interferon pathways, as well as key genes (IFNG and IFNGR1), were upregulated in NK cells in LAM. Interferon gamma expression is significantly upregulated in LAM-associated NK cells compared to that of healthy lungs. Dot size represents fraction of cells within that type expressing interferon gamma (IFNG). Dot colour intensity represents average expression within that cell type. c) Rapamycin treatment downregulated interferon pathways. Violin plot shows that both type I (IFN-α/β signalling via JAK/STAT) and type II (antimicrobial actions of IFN-γ pathway) interferon pathways were downregulated by rapamycin treatment of a primary culture of a TSC2-mutant angiomyolipoma. d) Rapamycin treatment downregulated interferon-induced genes in a primary culture of a TSC2-mutant angiomyolipoma. UMAP of cells in control group (red) and cells in rapamycin treatment group (cyan). Scale bar colour intensity represents imputed expressions. ***: p<0.001.

The percentage of type II pneumocytes expressing ACE2 in LAM lungs (2.6%) was significantly higher than in healthy lungs (0.9%; p=0.03, Mann–Whitney U-test) (figure 1a). Compared with healthy lungs, ACE2 expression was also higher in LAM-associated type I (1.5% versus 0.7%; p=0.14) and ciliated cells (1.1% versus 0.5%; p=0.39). TMPRRS2 expression was also significantly higher in LAM-associated type II pneumocytes (56% versus 45%; p=0.048) (figure 1a) and ciliated cells (33% versus 22%; p=0.14) compared to healthy lung. Significant upregulation of ACE2 was not observed in single cell datasets from other lung conditions compared to healthy lungs, including pulmonary fibrosis (GSE122960) (n=4) [9] and lungs with cancer (n=2) [8] and infectious diseases (n=6) [8], with the exception of one lung from an HIV-positive and Mycobacterium tuberculosis-positive patient (figure 1a) [8]. These observations indicate that increased pneumocyte expression of ACE2 and TMPRSS2 is specific to LAM and not seen in other lung conditions, and suggest that the mTORC1-hyperactive LAM cells may induce this effect.

We further investigated whether ACE2+/TMPRSS2+ cells in LAM are primed for infection beyond the expression of these receptors for virus entry. Gordon et al. [11] identified 332 human proteins physically interacting with severe acute respiratory syndrome coronavirus (SARS-CoV-2) proteins in HEK293T cell expression experiments. We calculated a COVID-19 module score based on the average expression of these 332 genes using Seurat [4] in LAM pneumocytes. The significant upregulation of COVID-19 module score was seen in ACE2+/TMPRSS2+ cells compared to ACE2+/TMPRSS2− cells (Mann–Whitney U-test, p=5.1×10−5) and ACE2−/TMPRSS2− cells (Mann–Whitney U-test; p=1.1×10−14) (figure 1a). Consistent with this, the percentage of cells expressing each of these 332 individual genes was highest in the ACE2+/TMPRSS2+ cells (Mann–Whitney U-test, p=2.2×10−16; ACE2+/TMPRSS2+ versus ACE2+/TMPRSS2−) and lowest in the ACE2−TMPRSS2− cells (Mann–Whitney U-test, p=2.2×10−16; ACE2+/TMPRSS2+ versus ACE2−/TMPRSS2−) (data not shown due to limited space). These analyses demonstrate that ACE2 expression in LAM correlates with increased expression of genes whose protein products interact with, and are hypothesised to enable virus replication.

To identify pathways co-regulated with the upregulation of ACE2 in LAM, we performed pathway analysis, comparing expression of ACE2+ versus ACE2− epithelial cells in the LAM dataset. Both hypoxia and IL-6-induced acute-phase response pathways were upregulated in the LAM ACE2+ pneumocytes. The master transcription factor of the IL-6 pathway, STAT3, was upregulated in LAM ACE2+ pneumocytes, along with four genes directly or indirectly regulated by STAT3: FGG, CXCL1, HP and HMOX1 (figure 1b), suggesting IL-6 might be driving these effects. Consistent with this, we found increased IL-6 in LAM-associated fibroblasts compared to mesenchymal cells derived from healthy lungs (figure 1b), supporting the concept that IL-6 drives ACE2 expression in LAM.

ACE2 is an interferon-stimulated gene in human airway epithelial cells [8]. We used lists of genes involved in interferon (IFN)-α/β signalling via JAK/STAT (type I) and IFN-γ (type II) signalling pathways (MetaCore from Clarivate Analytics) to calculate cell type-specific interferon pathway activity scores in healthy lungs compared with LAM lungs [4]. In the LAM lungs, both type I and type II interferon pathways were upregulated in natural killer (NK), but not in T cells, B cells or macrophages (figure 1b). Many key regulators in the interferon pathways were significantly upregulated in LAM NK cells, including INFG and INFGR1 (figure 1b). In addition, IFN-γ expression was upregulated in LAM-associated NK cells compared to healthy lungs (figure 1b). These analyses suggest that interferon secretion by LAM NK cells into the tumour microenvironment may cooperate with IL-6 to upregulate ACE2 expression in LAM epithelial cells (figure 1b).

mTORC1, which is hyperactive in LAM, promotes protein synthesis and cellular growth, and is believed to be used by SARS-CoV-2 to favour replication [12]. LARP1, an mTOR-regulated translational repressor, is among the 332 virus-interacting proteins identified by Gordon et al. [11], and Appelberg et al. [13] identified crosstalk between SARS-CoV-2 and mTOR/HIF-1 signalling. Therefore, we investigated the effect of rapamycin (an allosteric mTORC1 inhibitor) on gene expression in these pathways in primary cells, derived from a dissociated renal angiomyolipoma tumour carrying a TSC2 mutation obtained at the time of surgery. Angiomyolipomas are benign tumours that share common genetic mutations with LAM and occur in half of women with LAM. Primary cultures were treated with 20 nM rapamycin or DMSO for 24 h and subjected to single cell profiling. To overcome the challenge of inflated zeroes in single cell data, we used MAGIC [14] to impute gene expression in each cell. Using the same pathway gene lists described above (MetaCore from Clarivate Analytics), we observed that rapamycin treatment had major effects in downregulating both type I and type II interferon pathways (Mann–Whitney U-test, p<2.2×10−16 for all comparisons) (figure 1c), including many interferon-stimulated genes (e.g. IFIT, interferon induced protein with tetratricopeptide repeats family) (Mann–Whitney U-test p<0.001 for all genes) (figure 1d). IL-6-induced acute-phase response genes that were enriched in ACE2+ cells were also downregulated by rapamycin treatment (Mann–Whitney U-test, p<0.001) (figure 1d). The expression of the 332 SARS-CoV-2-interacting host proteins also showed downregulation by rapamycin treatment in general (data not shown due to limited space). These analyses suggest that mTORC1 inhibition may have benefit in SARS-CoV-2 infection by decreasing the interferon and IL-6 pathways that promote the expression of ACE2.

In conclusion, we observed an increased percentage of type II pneumocytes expressing ACE2 in LAM lungs, associated with upregulation of the type I and type II interferon pathways in LAM-associated NK cells, and increased IL6 expression in LAM-associated fibroblasts, suggesting that both mechanisms drive increased ACE2 expression. Similar mTORC1-dependent mechanisms may contribute to ACE2 expression in other settings. An advantage of using LAM as a model system is the consistent activation of mTORC1 within LAM cells. While other tumours often have elevated mTORC1 activity, it is rarely present as a single, defining genetic feature, making it much more difficult to pinpoint these types of non-cell autonomous mechanisms. How mTORC1 signalling within tumour cells impacts ACE2 expression in neighbouring epithelial cells will require additional single-cell datasets using genetically defined specimens, and/or mouse models in which mTORC1 is specifically perturbed. Alterations in mTORC1 signalling may also be present in non-malignant disorders, such as idiopathic pulmonary fibrosis (IPF). We analysed a published single cell dataset of four IPF samples, and did not find a significant increase in ACE2 expression in type II pneumocytes compared to healthy donors.

Notably, using cultured primary cells from a LAM-related tumour, angiomyolipoma, we discovered that rapamycin treatment downregulated the interferon pathways and also downregulated a set of previously identified putative SARS-CoV-2-interacting proteins. From a clinical perspective, the upregulation of ACE2/TMPRSS expression in LAM lung epithelial cells suggests that women with LAM may be at increased risk of severe COVID-19 infection. Although all of the LAM specimens studied here are from lung transplantation tissue representing advanced disease, since our analyses link mTORC1 activity to the expression of ACE2 and TMPRSS2, we speculate that this would also be true in mild disease. Future studies will be needed to confirm this. The downregulation of IL-6 and interferon signalling in response to rapamycin suggests that rapamycin treatment may have benefit both in limiting initial infection upon virus exposure and progression of COVID-19 to pneumonia both in general and in women with LAM. This is particularly important for patients already taking rapamycin for LAM or other diseases. Further analyses including clinical trials will be necessary to assess the potential benefit of rapamycin for both aspects of COVID-19.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-02737-2020.Shareable

Footnotes

  • Author contributions: Y. Tang, D.J. Kwiatkowski and E.P. Henske designed the study. Y. Tang performed all experiments, analysed data, interpreted the data and wrote the manuscript. D.J. Kwiatkowski and E.P. Henske reviewed and evaluated the data and revised the manuscript. All authors read and approved the manuscript.

  • Conflict of interest: Y. Tang has nothing to disclose.

  • Conflict of interest: D.J. Kwiatkowski has nothing to disclose.

  • Conflict of interest: E.P. Henske has nothing to disclose.

  • Support statement: Y. Tang is the recipient of a Career Development Award from The LAM Foundation and a grant from the DOD Tuberous Sclerosis Complex Research Program (W81XWH1910152- TS180029). We also thank the Rothberg Family for their support of this work. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received July 11, 2020.
  • Accepted October 4, 2020.
  • Copyright ©ERS 2021
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Wang D,
    2. Hu B,
    3. Hu C, et al.
    Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061–1069. doi:10.1001/jama.2020.1585
    OpenUrlCrossRefPubMed
  2. ↵
    1. Henske EP,
    2. McCormack FX
    . Lymphangioleiomyomatosis – a wolf in sheep's clothing. J Clin Invest 2012; 122: 3807–3816. doi:10.1172/JCI58709
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Butler A,
    2. Hoffman P,
    3. Smibert P, et al.
    Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 2018; 36: 411–420. doi:10.1038/nbt.4096
    OpenUrlCrossRefPubMed
  4. ↵
    1. Stuart T,
    2. Butler A,
    3. Hoffman P, et al.
    Comprehensive integration of single-cell data. Cell 2019; 177: 1888–1902. doi:10.1016/j.cell.2019.05.031
    OpenUrlCrossRefPubMed
  5. ↵
    1. Aran D,
    2. Looney AP,
    3. Liu L, et al.
    Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol 2019; 20: 163–172. doi:10.1038/s41590-018-0276-y
    OpenUrlCrossRefPubMed
  6. ↵
    1. Sungnak W,
    2. Huang N,
    3. Bécavin C, et al.
    SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 2020; 26: 681–687. doi:10.1038/s41591-020-0868-6
    OpenUrlCrossRefPubMed
    1. Qi F,
    2. Qian S,
    3. Zhang S, et al.
    Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun 2020; 526: 135–140. doi:10.1016/j.bbrc.2020.03.044
    OpenUrlPubMed
  7. ↵
    1. Ziegler CGK,
    2. Allon SJ,
    3. Nyquist SK, et al.
    SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 2020; 181: 1016–1035.e1019. doi:10.1016/j.cell.2020.04.035
    OpenUrlCrossRefPubMed
  8. ↵
    1. Reyfman PA,
    2. Walter JM,
    3. Joshi N, et al.
    Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis. Am J Respir Crit Care Med 2019; 199: 1517–1536. doi:10.1164/rccm.201712-2410OC
    OpenUrlPubMed
  9. ↵
    1. Cao Y,
    2. Li L,
    3. Feng Z, et al.
    Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov 2020; 6: 11. doi:10.1038/s41421-020-0147-1
    OpenUrl
  10. ↵
    1. Gordon DE,
    2. Jang GM,
    3. Bouhaddou M, et al.
    A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020; 583: 459–468. doi:10.1038/s41586-020-2286-9
    OpenUrlCrossRefPubMed
  11. ↵
    1. Kuss-Duerkop SK,
    2. Wang J,
    3. Mena I, et al.
    Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replication. PLoS Pathog 2017; 13: e1006635. doi:10.1371/journal.ppat.1006635
    OpenUrlCrossRefPubMed
  12. ↵
    1. Appelberg S,
    2. Gupta S,
    3. Ambikan AT, et al.
    Dysregulation in mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells. bioRxiv 2020; preprint [https://doi.org/10.1101/2020.04.30.070383].
  13. ↵
    1. van Dijk D,
    2. Sharma R,
    3. Nainys J, et al.
    Recovering gene interactions from single-cell data using data diffusion. Cell 2018; 174: 716–729 e727. doi:10.1016/j.cell.2018.05.061
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
View this article with LENS
Vol 57 Issue 2 Table of Contents
European Respiratory Journal: 57 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19
Yan Tang, David J. Kwiatkowski, Elizabeth P. Henske
European Respiratory Journal Feb 2021, 57 (2) 2002737; DOI: 10.1183/13993003.02737-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19
Yan Tang, David J. Kwiatkowski, Elizabeth P. Henske
European Respiratory Journal Feb 2021, 57 (2) 2002737; DOI: 10.1183/13993003.02737-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis
  • Ethical obligations for supporting healthcare workers during the COVID-19 pandemic
  • Reversible pulmonary hypertension with multivisceral Whipple's disease
Show more Agora

Research letters

  • Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis
  • Reversible pulmonary hypertension with multivisceral Whipple's disease
  • Lower lung function in patients recovering from COVID-19
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society